The skin is an attractive organ for immunization due to the presence of a large number of epidermal and dermal antigen-presenting cells. Hollow microneedles allow for precise and non-invasive intradermal delivery of vaccines. In this study, ovalbumin (OVA)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles with and without TLR3 agonist poly(I:C) were prepared and administered intradermally by hollow microneedles. The capacity of the PLGA nanoparticles to induce a cytotoxic T cell response, contributing to protection against intracellular pathogens, was examined. We show that a single injection of OVA-loaded PLGA nanoparticles, compared to soluble OVA, primed both adoptively transferred antigen-specific naïve transgenic CD8 + and CD4 + T cells with markedly high efficiency. Applying a triple immunization protocol, PLGA nanoparticles primed also endogenous OVA-specific CD8 + T cells. Immune response, following immunization with in particular anionic PLGA nanoparticles co-encapsulated with OVA and poly(I:C), provided protection against a recombinant strain of the intracellular bacterium Listeria monocytogenes, secreting OVA. Taken together, we show that PLGA nanoparticle formulation is an excellent delivery system for protein antigen into the skin and that protective cellular immune responses can be induced using hollow microneedles for intradermal immunizations.
Introduction
The skin is an organ with many immune cells and is considered a potent organ for immunizations [1] . However, the challenge is to deliver high-molecular-weight antigens across the stratum corneum, which is the outermost layer of the skin and acts as an effective natural barrier for penetration of pathogens and allergens into the skin. One of the methods to circumvent the skin barrier is the use of microneedles. Microneedles are miniaturized needles that provide the possibility of minimally invasive vaccination in the dermis and epidermis of the skin. There are other benefits in using microneedles compared to traditional hypodermic needles, like possible painless vaccination, the requirement of less trained personnel and reduced contamination risk [2] . Nowadays a wide variety of these microneedles exist, including solid, coated, dissolving and hollow microneedles [3, 4] .
Hollow microneedles have multiple benefits, for instance they can be used to inject a wide variety of fluids into the skin at different pressure-driven flow rates [3, 5, 6] and offer the highest precision in dose delivery among all microneedle types. Furthermore, they offer the possibility to screen formulations without time-consuming design and preparation of microneedles, as in case of coated and dissolving microneedles. Recently, hollow microneedles and an applicator for them were developed in our laboratory to inject formulations in precise manner into the skin. These microneedles were successfully used for formulations with inactivated polio virus vaccine in rats resulting in effective humoral immune responses [7] [8] [9] . However, whether hollow microneedle-mediated delivery may also induce CD8 + T cell responses towards vaccine antigens is presently unclear. Cytotoxic CD8 + T cells play an important role in cellular immune protection against intracellular pathogens or tumor growth. To induce such CD8 + T cell responses, an antigen needs to be processed in the cell and presented by MHC-I molecules on professional antigen-presenting cells (pAPC) to the immune system. Delivery of vaccine protein antigens over the cellular membrane can be achieved using delivery systems and over the past decades different types of them, such as polymeric nanoparticles, emulsions and lipid-based nanoparticles have been developed [10] [11] [12] . Nano-encapsulation of antigens has several advantages, such as stabilization of antigens in vivo, enhancement of the uptake by pAPC and also reduction of antigen release into systemic circulation [4, 13] . The immune outcome can be potentially shaped by using nanoparticles with difference size [14] and surface charge [15] , and by co-encapsulating antigen and adjuvant into the nanoparticles [16, 17] . For the production of polymeric nanoparticles, poly(lactic-co-glycolic acid) (PLGA) is the most commonly used polymer, because of its superior biocompatibility and biodegradability [18] [19] [20] . Previous studies have shown that model antigen-and adjuvant-loaded PLGA nanoparticles used for vaccination were able to improve the induction of cell-mediated immune response in mice [17, [21] [22] [23] . However, relatively little is known about how encapsulation in PLGA nanoparticles modifies T cell responses to antigen/adjuvant combinations that are delivered intradermally by different novel types of microneedles. One recent study reported that PLGA nanoparticles, delivered intradermally using dissolving microneedles arrays [24] , induced cellular immune responses and protection against viral infection and tumor growth.
In this study, nanoparticles were prepared and characterized in terms of size, surface charge and antigen/adjuvant release profiles. We investigated the ability of hollow microneedle-delivered protein antigens, encapsulated in either anionic or cationic PLGA nanoparticles without and with co-encapsulated TLR 3 agonist poly(I:C) to induce a protective, cellular immune response towards an intracellular pathogen in a mouse model.
Materials and methods

Materials
PLGA (acid terminated, lactide glycolide 50:50, Mw 24.000-38.000), polyethylenimine (PEI, linear, average M n 10,000), Roswell Park Memorial Institute medium (RPMI) and Fetal bovine serum (FBS) were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). PVA 4-88 (31 kDa) was obtained from Fluka (Steinheim, Germany). Endotoxin-free ovalbumin (OVA), polyinosinic-polycytidylic acid (poly(I:C)) (low molecular weight) and its rhodamine-labelled version were obtained from Invivogen (Toulouse, France). Alexa647 labelled OVA (OVA-Alexa647) was ordered from Thermo-Fischer Scientific (Waltham, MA). Dimethylsulfoxide (DMSO) was obtained from Biosolve BV (Valkenswaard, The Netherlands). Sodium dodecyl sulfate (SDS) was obtained from Merck Millipore (Hohenbrunn, Germany). Ammonium-Chloride-Potassium (ACK) lysis buffer (150 mM NH 4 CL, 1 mM NaHCO 3 ; pH 7.40) and 1 mM phosphate buffer (PB; pH 7.4) were prepared in the lab. Milli-Q water (18.2 MΩ/cm, Millipore Co., USA) was used for the preparation of solutions. Sterile phosphate buffered saline (PBS) was obtained from Braun (Oss, The Netherlands). All other chemicals used are of analytical grade.
Purification antibodies used for DynaBeads® selection were all made in house and included the following antibody clones: αCD11b (clone M1/70), αMHC-II (M5/114), αB220 (RA3-6B2), αCD4 (GK1.4), αCD8 (YTS169) and αCD25 (PC61). Purification antibodies for sorting via flow cytometry were αCD8-APC (53-6.7; eBioscience), CD44-FITC (IM7; eBioscience) and CD62L-PE (MEL-14; BD Bioscience) using a BD influx (BD Biosciences). For the detection of the adoptively transferred T cells the antibodies αCD45.2-PerCPCy5.5 (104; eBioscience), αCD4-PE (GK1.5; eBioscience) and αCD8-APC (53-6.7; BD Bioscience) were used. Detection of the endogenous T cells was measured using the antibodies αCD8-APC (53-6.7; eBioscience), αCD4-eFluor450 (GK1.5; eBioscience), αCD62L-Horizon B510 or αCD44-FITC (IM7; eBioscience), αCD16/CD32-unstained (2.4G2; made in house) and αIFNγ-PE (XMG1.2; eBioscience).
Preparation of PLGA nanoparticles
OVA-loaded PLGA nanoparticles were prepared by double emulsion with solvent evaporation method as previously reported with modifications [25] . Briefly, 75 μl OVA (20 mg/ml) in PBS was dispersed in 1 ml PLGA (25 mg/ml) in ethyl acetate by a Branson sonifier 250 (Danbury, USA) for 15 s with a power of 20 W. To prepare anionic OVA-loaded PLGA nanoparticles (anPLGA-OVA), the obtained water-inoil emulsion was emulsified with 2 ml 2% (w/v) PVA with the sonifier (15 s, 20 W) to get a water-in-oil-in-water double emulsion. In case of cationic OVA-loaded PLGA nanoparticles (catPLGA-OVA), the single emulsion was emulsified with 2 ml 2% (w/v) PVA and 4% (w/v) PEI solution. The double emulsion was added dropwise into 25 ml 0.3% (w/ v) PVA (40°C) under stirring. The ethyl acetate was evaporated by a rotary evaporator (Buchi rotavapor R210, Switzerland) for 3 h (150 mbar, 40°C). The nanoparticle suspension was centrifugated (Avanti™ J-20XP centrifuge, Beckman Coulter, Brea, CA) at 35000 g for 10 min, washed twice with 1 mM PB to remove the excess OVA and PVA, and dried in a Alpha1-2 freeze dryer (Osterode, Germany, − 49°C, 90 mbar) overnight. To prepare OVA and poly(I:C) co-encapsulated PLGA nanoparticles (anPLGA-OVA-PIC), 18.75 μl OVA (40 mg/ml) and 75 μl poly(I:C) (46.7 mg/ml, including 0.03% fluorescently labelled equivalent) were emulsified with 1 ml PLGA (25 mg/ml) in ethyl acetate to obtain the water-in-oil emulsion. The remaining of the procedure was identical to that of anPLGA-OVA. The obtained nanoparticles were stored at 4°C for analysis and further use. To prepare the PLGA nanoparticles for release study, 10% of total OVA was replaced with OVA-Alexa647 the preparation.
Characterization of PLGA nanoparticles
The size (Z-average) and polydispersity index (PDI) of nanoparticles were measured by dynamic light scattering and the zeta potential of nanoparticles was measured by laser doppler velocimetry using a Nano ZS® zetasizer (Malvern Instruments, Worcestershire, U.K.). The samples were diluted with 1 mM PB buffer to a nanoparticle concentration of 25 μg/ml before each measurement. To determine the loading efficiency of OVA and poly(I:C) in PLGA nanoparticles, approximately 1 mg of nanoparticles were dissolved in a mixture of 15% (v/v) DMSO and 85% (v/v) 0.05 M NaOH and 0.5% SDS. The amount of OVA was determined by MicroBCA method following the manufacturer's instructions. The amount of poly(I:C) was quantified by the fluorescence intensity of rhodamine labelled poly(I:C) (λ ex 545 nm/λ em 576 nm). The encapsulation efficiency (EE) and loading capacity (LC) of OVA and poly(I:C) in the nanoparticles were calculated as below:
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where M loaded OVA/poly(I:C) represents the mass of loaded OVA or poly (I:C), M total OVA/poly (I:C) is the total amount of OVA or poly(I:C) added to the formulation and M nanoparticles is the weight of nanoparticles.
2.4.
Release of OVA and poly(I:C) from PLGA nanoparticles Nanoparticles were prepared in triplicate as described above. To study the release of OVA and poly(I:C) from PLGA nanoparticles, 3 mg anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC were dispersed into 1 ml RPMI supplemented with 10% FBS and incubated at 37°C with a shaking speed of 350 rpm. At different time points, the suspensions were centrifugated (9000g, 5 min) with Sigma 1-15 centrifuge (Osterode, Germany). A release sample of 600 μl of the supernatant was collected and replaced by fresh medium. The released amount of OVA and poly(I:C) was determined by fluorescence intensity of OVA-Alexa647 (λ ex 647 nm/λ em 671 nm) and rhodamine labelled poly(I:C) (λ ex 545 nm/λ em 576 nm), respectively.
Mice and intradermal immunizations
8-18 week old male B6·SJL/ptprcaPep3b/BoyCrl (B6·SJL) wild type mice and 8-30 week old transgenic (tg) mice that express pOVA 323-339 -specific T cell receptor (OT-II mice) or pOVA 257-264 -specific T cell receptor (OT-I mice) were initially obtained from Charles River and were bred in house. Abdomen of mice were shaved prior to immunization on both flanks and intradermal immunization was done using a single hollow microneedle as reported previously [8, 9] . The hollow microneedle was inserted into the abdomen of mice using an applicator controlling precisely the depth, volume and rate of the injections. The injections were performed at a depth of 120 μm, with a volume of 40 μl in 3 injections (2 right flank, 1 left flank) and with a rate of 10 μl/min. The depth was increased up to 200 μm if leakage was observed at the beginning of injection. In all experiments a total of 5 μg OVA or 50 μg OVA peptides were injected per immunization. In case of anPLGA-OVA-PIC, the dose of poly(I:C) was also 5 μg. Ethical approval was given by the Animal Ethics Committee from Utrecht University, The Netherlands.
Adoptive transfer of OVA T cell receptor (TCR) tg T cells
OVA-specific T cell transferred mice were obtained by injecting OT-I CD8 + and OT-II CD4 + T cells into wildtype B6·SJL mice. In order to obtain OT-I and OT-II cells, spleens were isolated from OT-I and OT-II mice and erythrocyte-depleted splenocytes were obtained as follows.
Single cell suspensions were prepared by passage over a 70 μM cell strainer after homogenizing the spleens with a syringe plunger, in RPMI 1640 GlutaMAX supplemented with 8.5% fetal calf serum (Bodinco), 30 μM 2-mercaptoethanol and penicillin/streptomycin (complete RPMI medium). The erythrocytes were depleted by lysis with ACK lysis buffer. Transgenic naïve CD4 + (OT-II) cells and transgenic CD8 + (OT-I) cells were isolated from splenocytes by negative selection using Magnetic DynaBeads® (Thermo Fisher Scientific, Waltham, MA). Antibodies used were αCD11b, αMHC-II, αB220 and either αCD4 for CD8 (OT-I) T cell purification or αCD8 and αCD25 for naïve CD4 + (OT-II) T cell purification. After negative selection by magnetic beads, a purity around 70% was achieved for naïve tg CD4 + (OT-II) T cells. injected into the tail vein of recipient mice, one day before immunization to obtain OVA-specific T cell transferred mice.
In vivo proliferation of adoptively transferred T cells
OVA-specific T cell transferred mice were immunized with OVA, anPLGA-OVA and catPLGA-OVA at day 0. PBS and OVA peptide immunizations were used as negative and positive controls, respectively. Proliferation of tg T cells was studied at day 3, 5 and 7. Next, 2. H-Thymidine (0.4 μCi/well; Amersham Biosciences Europe GmbH) was added for an additional 18 h and incorporation into DNA was measured by liquid scintillation counting (Microbeta, Perkin-Elmer Inc.). CD8 + T cell activation was measured using intracellular IFNγ staining as described previously [26] . In short, 2.5 × 10 6 erythrocytedepleted splenocytes were incubated in complete RPMI medium with 1 μg/ml pOVA 257-264 (Genscript) or complete RPMI medium and 10 μM monensin (eBioscience) for 6 h at 37°C in 6% humidified incubator. Cells were stained with either αCD8 antibody, αCD4, αCD62L or αCD44 in the presence of αCD16/CD32 to block Fc-receptors. Next, they were fixed with 2% paraformaldehyde and stained with αIFNγ antibody in the presence of 0.05% saponin. Samples were measured on a FACSCanto II (BD Biosciences) and analyzed using FlowJo software (Tree Star).
CFU counts in bacterial challenge study
B6·SJL mice were immunized with OVA, OVA + PIC, anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC at day 0, 3 and 6. Mice were challenged with recombinant Listeria monocytogenes secreting OVA (rLM-OVA) 21 days after final immunization. Mice immunized with 10.000 CFU rLM-OVA at day 6 were used as positive control and unimmunized mice served as negative control. rLM-OVA [27, 28] were cultured in Brain Hart Infusion broth (BHI; Sigma-Aldrich) with 5 μg/ ml erythromycin and to challenge the mice 100.000 bacteria from a LOG-phase culture were injected in 200 μl/mouse in the tail vain. To study the elimination of bacteria, three days after challenge spleens were isolated and single cell suspensions were made in RPMI medium. Serial dilutions were plated on BHI agar plates and CFU counts were determined after approximately 36 h in a 37°C incubator. The remaining mice were sacrificed 5 days after the challenge to study the CD4 + and CD8 + T cell response. The specific T cell response was determined in spleen using intracellular IFN-γ staining method as described in section 8. 
Statistics
Statistical significance was determined using Krukal-Wallis and multiple comparison/post hoc analysis was done with Dunn's correction, * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
Results
Preparation and characterization of PLGA nanoparticles
The physicochemical characteristics of PLGA nanoparticles are shown in Table 1 . PLGA nanoparticles had a size of approximately 150 nm with a low PDI ranging from 0.032 to 0.100. AnPLGA-OVA had a negative surface charge with a zeta potential of approximately − 18 mV and catPLGA-OVA possessed a positive surface charge with an opposite zeta potential around + 10 mV. The EE% of OVA was approximately 50% in both anPLGA-OVA and anPLGA-OVA-PIC, and catPLGA-OVA showed a significantly higher EE%. CatPLGA-OVA had also a higher LC% (10.4%) of OVA than anPLGA-OVA (6.6%) and anPLGA-OVA-PIC (2.8%). The ratio between the initial amounts of OVA and poly(I:C) in the formulations during the preparation procedure was adjusted in order to prepare anPLGA-OVA-PIC with similar LC% of OVA (2.8%) and poly(I:C) (2.7%).
The formulations are characterized in terms of size (diameter) and poly disperse index (PDI), zeta potential (ZP), and encapsulation efficiency (EE) and loading capacity (LC) of OVA and poly(I:C). The EE% of OVA or poly(I:C) was defined as the percentage of encapsulated amount of OVA or poly(I:C) compared to the added amount of OVA or poly(I:C). The LC% of OVA or poly(I:C) was defined as the percentage of encapsulated amount of OVA or poly(I:C) compared to the amount of nanoparticles. anPLGA-OVA: OVA-loaded PLGA nanoparticles with negative surface charge. catPLGA-OVA: OVA-loaded PLGA nanoparticles with positive surface charge. anPLGA-OVA-PIC: OVA and poly (I:C) co-encapsulated anionic PLGA nanoparticles.
Release of OVA and poly(I:C) from PLGA nanoparticles
Release of OVA and poly(I:C) from PLGA nanoparticles was measured in vitro in culture medium containing serum (Fig. 1) . The developed nanoparticles showed a burst release of OVA within the first day, followed by a slow release. At day 30 approximately 49%, 22% and 26% OVA was released from anPLGA-OVA, catPLGA-OVA and anPLGA-OVA-PIC, respectively. In case of poly(I:C), anPLGA-OVA-PIC followed the trend of OVA. At day 30, around 42% poly(I:C) was released. Thus, all of the PLGA nanoparticles released at most one half of their content within one month time.
OVA-loaded PLGA nanoparticles enhances antigen-induced activation of tg T helper cells and enables priming of tg cytotoxic T cells after intradermal immunization using a hollow microneedle
To determine the induction of a cellular immune response towards a protein antigen that is delivered via hollow microneedles, we first examined the ability of a protein antigen to activate transgenic (tg) T cells that were adoptively transferred ( Fig. 2A) . Naïve OVA specific CD4 + and CD8 + T cells were isolated from spleens of OT-II and OT-I mice, expressing a tg T Cell Receptor specific for the CD4 + and CD8 + T cell epitopes (OVA 323-339 and OVA 257-264 ) of the model antigen OVA, respectively [29, 30] . After staining with cell trace dyes, these cells were mixed and transferred into congenic recipient mice, allowing the distinction between host and donor T cells in flow cytometry, based on expression of the congenic marker ( Fig. 2A) . One day later the recipient mice were immunized intradermally, using a hollow microneedle, with full length OVA protein or with the OVA epitopes (pOVA). These epitopes do not require any antigen processing in order to activate tg T cells and served as a positive control. We first determined if CD4 + T helper cells were activated in the present study. Tg CD4 + T cells were detected in flow cytometry as CD4 + CD45.2 + T cells within the lymphocyte gate in either draining inguinal lymph nodes (dLN) or in the spleens. In OVA protein-immunized mice, a small increase in numbers of tg CD4 + T cells compared to PBS group was found in the dLN at day 5 after immunization, while in mice immunized with peptides numbers of tg CD4 + T cells were higher in both dLN and spleen (Fig. 2B) . In mice immunized with OVA protein, minimal systemic responses were measured in the spleen at day 7 (Fig. 2C, F) , and furthermore, minimal numbers of transferred CD4 + T cells activated by OVA protein were fully proliferated ( Fig. 2D-F ; depicted by > 6 dilutions of cell trace dye). We then determined whether OVA encapsulation in PLGA nanoparticles could enhance OVA-specific tg CD4 + T cell responses. When mice were immunized with OVA-loaded anionic and cationic PLGA nanoparticles (PLGA-OVA), we detected high numbers of OVA-specific tg CD4 + T cells in dLN, both at day 5 and 7 post-immunization (Fig. 2B) . And in spleen these numbers were also significantly higher (Fig. 2C ) than in mice immunized with soluble OVA. Total numbers of tg CD4 + T cells retrieved from PLGA nanoparticle immunized mice were also much higher than in mice immunized with peptide (Fig. 2B,  C) . Over 95% of these cells were fully proliferated in anPLGA-OVA and catPLGA-OVA groups, while OVA induced only slightly more fully proliferated cells than PBS locally on day 5 and systemically on day 7.
Immunizing with the OVA peptides showed a high proliferation rate at day 5 only, while at day 7 the numbers of fully proliferated cells dropped (Fig. 2E-F) . No differences were observed between responses Fig. 1 . Release of OVA and poly(I:C) from PLGA nanoparticles. PLGA nanoparticles were dispersed into culture medium containing serum and incubated at 37°C. At different time points, the release sample was collected to determine the release amount of OVA (A) and poly(I:C) (B). Data is presented as mean ± SEM, n = 3.
detected against anPLGA-OVA and catPLGA-OVA. Taken together, we show that encapsulation in PLGA nanoparticles enhanced the activation of tg T helper cells by OVA after intradermal immunization using hollow microneedles. Next, it was determined if the followed immunization strategy also induced a cytotoxic cellular immune response, to provide protection against intracellular pathogens or tumors. Activation and proliferation of CD8 + tg T cells was measured in the same experimental setup as shown in Fig. 2A . As expected, no increase in the numbers of tg CD8 + T cells was detected in either dLN or spleen at day 3, 5 or 7 after immunization with soluble OVA protein (Fig. 3A, B) . On day 3, immunization with OVA induced some T cell proliferation, as shown by dilution of cell trace dye (Fig. 3C, D) , although this proliferation did not lead to a significant increase in tg CD8 + T cell numbers (Fig. 3A, B) . In contrast, immunization with OVA-loaded PLGA nanoparticles, induced a marked increase in tg CD8 + T cell numbers not only in dLN but also in spleen, as detected at both days 5 and 7 (Fig. 3A, B) . Most of these cells were fully proliferated and there was no difference observed between responses induced by anPLGA-OVA and catPLGA-OVA. Immunization with OVA peptides also induced a systemic tg CD8 + T cell response, detected at day 5, but in contrast to nanoparticle-immunization, this response decreased significantly at day 7 in spleen as well as dLN. This was probably due to differing kinetics of T cell responses triggered by precise T cell epitopes, compared to full length OVA, which requires prior antigen processing. In conclusion, our data indicate that encapsulation in PLGA nanoparticles enables OVA to trigger CD8 + tg T cell responses upon hollow microneedle-mediated intradermal delivery.
OVA primes both endogenous CD4 + and CD8 + T cell responses in immunized hosts when particulated in PLGA nanoparticles or adjuvanted with TLR3 agonist
Having shown that hollow microneedle-mediated immunization with OVA-loaded PLGA nanoparticles activates adoptively transferred tg T cells (Figs. 2 and 3) , we next examined whether this strategy also primes endogenous T cell responses in immunized hosts. To this end, wild type mice were immunized at day 0, 3 and 6 with either OVA, OVA adjuvanted with TLR3 agonist poly(I:C) (OVA + PIC), anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC (Table 1 ; Fig. 4A ). At day 13, antigen-specific CD8 + T cell responses were detected by intracellular IFNγ cytokine staining ( Supplementary Fig. 1A ). Background levels of IFNγ produced by CD8 + T cells was low in all mice, as depicted by restimulation of cells with medium (Fig. 4B, C) . As expected, no OVA 257-264 -specific CD8 + T cell response was detected in mice immunized with soluble OVA (Fig. 4B, C) . In contrast, responses to this epitope were clearly detectable in dLN (Fig. 4B ) and the spleen (Fig. 4C ) of mice immunized with either OVA + PIC, as well as catPLGA-OVA or anPLGA-OVA. Responses in the anPLGA-OVA mouse group tended to be lower than in the catPLGA-OVA group. The addition of poly(I:C) enhanced the response induced by anPLGA-OVA immunization, although OVA-PIC only already showed some CD8 activation as well (Fig. 4B, C) . Thus, following hollow microneedle-mediated delivery, a specific recipient CD8 + T cell response is induced by OVA when encapsulated in cationic PLGA nanoparticles or when adjuvanted with TLR3 agonist with or without anionic PLGA nanoparticles. Furthermore, induction of OVA-specific CD4 + T cell responses in the immunized mice was determined by measuring 3 H-thymidine incorporation in 72 h splenocyte cultures incubated with OVA protein. Some OVA-specific proliferation was detected in mice immunized with OVA + PIC, catPLGA-OVA, and anPLGA-OVA-PIC (Fig. 4D) , although no significant differences between groups were observed.
Thus, hollow microneedle-mediated, intradermal immunization with PLGA nanoparticle encapsulated OVA with or without poly(I:C) induces clearly detectable OVA 257-264 -specific CD8 + T cell responses and minor OVA-specific CD4 + T cell responses in mice. + and divided > 6 times as measured by CFSE intensity on day 5 or 7 in either dLN (E) or spleen (F) after intradermal immunization via hollow microneedles with the formulations indicated on x axes. Graphs are representative for 1 of total 2 independent experiments. Per experiment the number of mice used is n = 4 for OVA, anPLGA-OVA and catPLGA immunization groups, n = 3 for pOVA immunization groups, n = 2 for PBS immunization group (as depicted by the number of symbols in the graph). Statistical significance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing immunization strategies versus PBS or OVA immunization with Dunn's correction, *p < 0.05.
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3.5. Protective immune response towards recombinant rLM-OVA after intradermal immunization using hollow microneedles CD8 + T cells play an essential role in clearance of the intracellular bacterium Listeria monocytogenes [31] . Next, we determined whether hollow microneedle-mediated vaccination with PLGA nanoparticles induces protective immunity against rLM-OVA. Mice were immunized with OVA, OVA-PIC, anPLGA-OVA, catPLGA-OVA or anPLGA-OVA-PIC at day 0, 3 and 6 and challenged with the bacterium, 21 days after final immunizations (Fig. 5A ). Unimmunized mice served as a negative control and mice immunized with rLM-OVA at day 6 served as positive control, as these mice are typically able to completely clear the bacterium within 3 days after challenge. Determination of CFU counts in the spleens at day 30 showed that mice immunized with rLM-OVA indeed completely cleared the challenge dose, while spleens of non-immunized mice contained on average approximately 100.000 bacteria (Fig. 5B ). While immunization with soluble OVA, anPLGA-OVA or OVA-PIC failed to protect (Fig. 5B) , protection was observed in at least one mouse immunized with catPLGA-OVA. Moreover, anPLGA-OVA-PIC induced full protection, resulting in zero bacteria count in the spleen, similar to mice immunized with rLM-OVA. This indicates that immunization with anPLGA-OVA-PIC, and to some degree catPLGA-OVA, via the intradermal route using hollow microneedles, elicits a protective cellular immune response.
To study the possible relation between T cell response and the capacity to clear the pathogen, the T cell response in the spleen of the mice was measured. Quantification of T cell responses 5 days after challenge with rLM-OVA showed that all immunization regimens triggered OVA-specific CD4 + T cell responses, and that poly(I:C) did not further increase these responses (Fig. 5C ). In all immunized groups except for OVA-immunized mice a particularly robust activation of antigen-specific CD8 + T cells was detected (Fig. 5D) Fig. 1B-D ; dotted line). We found higher CD44 int :CD44 hi cell ratios in mice that had received anPLGA-OVA-PIC, catPLGA-OVA and rLM-OVA, i.e. the immunization regimens that led to reduced CFU counts following bacterial challenge (Fig. 5E) . Thus, the presence of antigenspecific CD44 int CD8 + T cells seems favorable for immune protection to rLM-OVA infection.
Discussion
Nowadays, most of the vaccines under investigation are based on recombinant proteins or subunits of pathogens, because of improved safety and lower production cost compared to live or attenuated vaccines [32] . However, generally such vaccines are poorly immunogenic and fail to elicit robust cell-mediated immunity against intracellular pathogens. In this respect, nanoparticle-based delivery of antigens may be an attractive tool, because it can improve immune immunization via hollow microneedles with the formulations indicated on X-axes. Graphs are representative for 1 of total 2 independent experiments. Per experiment the number of mice used is n = 4 for OVA, anPLGA-OVA and catPLGA immunization groups, n = 3 for pOVA immunization groups, n = 2 for PBS immunization group (as depicted by the number of symbols in the graph). Statistical significance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing immunization strategies versus PBS immunization with Dunn's correction, *p < 0.05.
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response induction to encapsulated antigens [33] . In this study, OVA was used as a model antigen and encapsulated into PLGA nanoparticles with or without the adjuvant poly(I:C). The capacity of the nanoparticle formulations to stimulate cell-mediated immunity was investigated by intradermal immunization using hollow microneedles. In this study, we show that intradermal delivery using hollow microneedles can elicit a protective cellular immune response when the antigen is encapsulated in cationic or adjuvanted anionic PLGA nanoparticles. These data expand on previous studies using hollow microneedles where humoral immune responses were detected [7] [8] [9] , which illustrated the attractiveness of the intradermal route for the delivery of vaccines. In our studies, we elaborated on the potential to induce CD8 + T cells in the skin using microneedles, specifically using hollow microneedles. Nanocarriers used for delivery of proteins or subunit vaccines enhance antigen uptake by antigen presenting cells and contribute to a prolonged presentation of the vaccine antigen at the cell surface [34, 35] . This leads to activation of a cellular immune response, which was exemplified in previous studies showing that PLGA nanoparticleencapsulated antigens, with or without adjuvant, may induce strong T helper type 1 and cytotoxic T cell immune response (Th1/CTL) response when delivered systemically or subcutaneously [15, 17, 36] . However, relatively little is known about the immune responses elicited by nanoparticle vaccines when administered intradermally using microneedles. On the one hand, inducing conduits in the skin with microneedles and subsequent application of nanoparticles, loaded with either OVA or antigen-encoding cDNA, induced an immune response [37, 38] . Nevertheless, this method of delivery differs from intradermal administration by microneedles. On the other hand, some previous studies on model subunit vaccines using microneedles, such as nanopatches to deliver non-encapsulated TLR adjuvants or pH sensitive microneedles arrays loaded with high doses of protein induced CD8 + T cell responses [39] [40] [41] . However, in these studies using microneedles none of the vaccine antigens were encapsulated in nanoparticles. In one study, dissolving microneedles loaded with PLGA nanoparticle encapsulated antigens were used for intradermal vaccination, and shown to induce a robust antigen-specific protective cellular immune response in mice [24] .
Our data show that hollow microneedle-delivered nanoencapsulated OVA not only activated transferred tg T cells, but also primed endogenous protective CD8 + T cell responses in immunized mice. In mice adoptively transferred with tg T cells, an endogenous T cell response could not be detected (not shown). This may be explained by the single injection immunization regimen in these studies, which may be sufficient to prime adoptively transferred tg CD8 + T cells, but not the naïve antigen-specific T cell repertoire. Alternatively, interference of the relatively easily activated tg T cells with priming of naïve T cells of recipient mice, for example by cytotoxicity towards antigen presenting pAPC as part of an immune homeostasis feedback loop, may also explain this observation. For this reason, to examine whether hollow microneedle-mediated immunization with PLGA nanoparticles encapsulated OVA may prime OVA-specific endogenous CD8 + T cells in mice, a priming procedure was used consisting of three immunizations delivered over a time period of 6 days. This protocol had been shown to induce cellular immune responses following dermal DNA tattoo immunization [26, 42] , but not yet when using hollow microneedles [7] . We report here that this prime boost protocol indeed elicits vigorous CD8 + T cell responses in mice immunized with PLGA encapsulated antigen, when using hollow microneedles as delivery method. A variety of dendritic cells in the dermis and epidermis have been shown to contribute to immune activation following dermal immunization [43, 44] , and they all express diverse pathogen recognition receptors, such as Toll-like receptors (TLRs). In agreement with this observation, multiple intradermal immunization studies using different administration methods have shown added effects of different Toll-like receptor (TLR) agonists based adjuvants [16, 45] . In our study, co-delivery of OVA and the TLR3 agonist poly(I:C) in PLGA nanoparticles, led to protective cellular immune responses to rLM-OVA. Possibly, the nanoparticles act as a depot system and stimulate the immune system by controlling the release of OVA and poly(I:C), resulting in prolonged OVA presentation and enhanced immunogenicity [23] .
Positively charged cationic PLGA nanoparticles are considered to be more immunogenic than anionic PLGA nanoparticle, as their positive surface charge facilitate the interaction with anionic cell membranes, enhancing uptake of these nanoparticles by phagocytic cells [46] . However, this enhanced interaction can also lead to increased cell cytotoxicity [10] , contributing to the challenges faced for therapeutic use in humans. In our adoptive transfer studies anPLGA-OVA and catPLGA-OVA seemed to perform equally well. However, catPLGA-OVA primed the endogenous cellular immune responses efficiently, while anPLGA-OVA did not show significant increase of response compared to OVA. Although one mouse showed full protection from subsequent infection with rLM-OVA after immunization with catPLGA-OVA, no statistical H-thymdine in DNA was measured liquid scintillation counting as CCTM. Statistical significance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done comparing all immunization groups with Dunn's correction, *p < 0.05, **p < 0.01, ***p < 0.001. difference in degree of immune protection induced by cationic compared to anionic PLGA-OVA was detected. Inclusion of poly(I:C) in the anionic nanoparticles was needed to fully protect immunized mice from infection.
Remarkably, although immune protection differed between mice immunized with OVA particulated in cationic or anionic PLGA without or with poly(I:C), vigorous OVA-specific CD8 + T cell responses were detected in all mouse groups except for mice immunized with soluble OVA. Difference in antigen release can have a role in shaping the memory phenotype [47] , however we found similar release profiles. 5 . Protective immune response towards rLM-OVA after hollow microneedle mediated intradermal immunization (A) Schematic overview of challenge study in which the mice received an i.v. challenge of 100.000 recombinant Listeria monocytogenes-OVA 21 days after 3 immunizations with OVA with or without negatively or positively charged PLGA NP or with or without poly(I:C). CFU count of rLM-OVA in spleen was determined 3 days after challenge and T cell activation was measured 5 days after challenge. (B) Spleens were isolated and serial dilutions were plated on BHI agar plates and CFU's were counted 36 h after incubation at 37°C. (C) CD4 + T cell and (D + E) CD8 + T cell responses were measured identical to procedure Fig. 3B+D in spleens. Gentamycin was added to culture medium to prevent further growth of potential rLM-OVA. Per experiment n = 4 for OVA, anPLGA-OVA and catPLGA immunization groups, n = 3 for pOVA immunization groups, n = 2 for PBS immunization group (as depicted by the number of symbols in the graph). Statistical significance was determined using Kruskal-Wallis, p < 0.05 and multiple comparison/post hoc analysis was done with Dunn's correction, *p < 0.05.
